OPG, RANK and RANK ligand expression in thyroid lesions

[1]  D. Heymann,et al.  Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. , 2007, Oncology reports.

[2]  J. Golledge,et al.  Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2. , 2007, Cardiovascular research.

[3]  B. Pitard,et al.  Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. , 2007, Cancer research.

[4]  S. Vukicevic,et al.  Thyroid‐Stimulating Hormone Restores Bone Volume, Microarchitecture, and Strength in Aged Ovariectomized Rats* , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  D. Heymann,et al.  RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases , 2007, Cellular and Molecular Life Sciences.

[6]  M. Mussap,et al.  Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study. , 2007, Metabolism: clinical and experimental.

[7]  A. Boyde,et al.  Thyroid hormone excess rather than thyrotropin deficiency induces osteoporosis in hyperthyroidism. , 2007, Molecular endocrinology.

[8]  B. Le Goff,et al.  DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process. , 2007, Bone.

[9]  B. Le Goff,et al.  Human osteosarcoma cells express functional receptor activator of nuclear factor‐kappa B , 2007, The Journal of pathology.

[10]  M. Padrines,et al.  Key roles of the OPG–RANK–RANKL system in bone oncology , 2007, Expert review of anticancer therapy.

[11]  Y. Hattori,et al.  Correlation between Serum Osteoprotegerin and Biomarkers of Bone Metabolism during Anti-Thyroid Treatment in Patients with Graves’ Disease , 2006, Hormone Research in Paediatrics.

[12]  H. Stettner,et al.  Receptor activator of nuclear factor κB ligand and osteoprotegerin in men with thyroid cancer , 2006, European journal of clinical investigation.

[13]  L. Pham,et al.  Nuclear Localization in the Biology of the CD40 Receptor in Normal and Neoplastic Human B Lymphocytes* , 2006, Journal of Biological Chemistry.

[14]  S. M. Sims,et al.  Regulation of cancer cell migration and bone metastasis by RANKL , 2006, Nature.

[15]  Y. Kadono,et al.  Osteoimmunology: interplay between the immune system and bone metabolism. , 2006, Annual review of immunology.

[16]  C. Ahn,et al.  Clinical features of bone metastases resulting from thyroid cancer: a review of 28 patients over a 20-year period. , 2005, Endocrine journal.

[17]  J. Patsch,et al.  Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. , 2005, The Journal of clinical endocrinology and metabolism.

[18]  M. Inaba,et al.  Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function. , 2005, European journal of endocrinology.

[19]  Z. Lin-shuang,et al.  Alteration of plasma concentrations of OPG before and after levothyroxine replacement therapy in hypothyroid patients , 2005, Journal of endocrinological investigation.

[20]  S. Théoleyre,et al.  The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. , 2004, Cytokine & growth factor reviews.

[21]  B. Biondi,et al.  Recombinant Human TSH Modulates In Vivo C‐Telopeptides of Type‐1 Collagen and Bone Alkaline Phosphatase, but Not Osteoprotegerin Production in Postmenopausal Women Monitored for Differentiated Thyroid Carcinoma , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  K. Chihara,et al.  Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL–RANK interaction , 2004, Journal of cellular physiology.

[23]  B. Biondi,et al.  High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. , 2004, Bone.

[24]  C. Wiedermann,et al.  Expression and function of RANK in human monocyte chemotaxis. , 2004, Arthritis and rheumatism.

[25]  S. Spitzer,et al.  Triiodothyronine (T3) and 1,25-dihydroxyvitamin D3 (1,25D3) Inversely Regulate OPG Gene Expression in Dependence of the Osteoblastic Phenotype , 2004, Calcified Tissue International.

[26]  M. Zaidi,et al.  TSH Is a Negative Regulator of Skeletal Remodeling , 2003, Cell.

[27]  J. Goldman,et al.  Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. , 2003, Blood.

[28]  Brian D. Strahl,et al.  A nucleosomal function for IκB kinase-α in NF-κB-dependent gene expression , 2003, Nature.

[29]  P. Pietschmann,et al.  Serum levels of osteoprotegerin increase with age in a healthy adult population. , 2003, Bone.

[30]  Raoul Rooman,et al.  Dexamethasone differentially inhibits thyroxine- or growth hormone-induced body and organ growth of Snell dwarf mice. , 2003, Endocrinology.

[31]  L. Mosekilde,et al.  Age-related changes in cortical bone content of insulin-like growth factor binding protein (IGFBP)-3, IGFBP-5, osteoprotegerin, and calcium in postmenopausal osteoporosis: a cross-sectional study. , 2003, The Journal of clinical endocrinology and metabolism.

[32]  A. Wells,et al.  Signalling shortcuts: cell-surface receptors in the nucleus? , 2002, Nature Reviews Molecular Cell Biology.

[33]  K. Nakao,et al.  A novel interaction between thyroid hormones and 1,25(OH)(2)D(3) in osteoclast formation. , 2002, Biochemical and biophysical research communications.

[34]  K. Makino,et al.  Nuclear localization of EGF receptor and its potential new role as a transcription factor , 2001, Nature Cell Biology.

[35]  P. Hersey,et al.  Differential Localization and Regulation of Death and Decoy Receptors for TNF-Related Apoptosis-Inducing Ligand (TRAIL) in Human Melanoma Cells1 , 2000, The Journal of Immunology.

[36]  D. Forrest,et al.  Mice devoid of all known thyroid hormone receptors are viable but exhibit disorders of the pituitary-thyroid axis, growth, and bone maturation. , 1999, Genes & development.

[37]  W. Min,et al.  The N-terminal domains target TNF receptor-associated factor-2 to the nucleus and display transcriptional regulatory activity. , 1998, Journal of immunology.

[38]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[39]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[40]  H. Kawaguchi,et al.  Comparison of the effects of 3,5,3′‐triiodothyroacetic acid and triiodothyronine on bone resorption in cultured fetal rat long bones and neonatal mouse calvariae , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[41]  M. Hansen,et al.  Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  D. Heymann,et al.  Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. , 2003, The American journal of pathology.

[43]  L. Hofbauer,et al.  Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland , 2002, Journal of cellular biochemistry.